Aspire Biopharma Holdings, Inc.
ASBP
$5.17
-$0.35-6.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.30K | 1.90K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.30K | 1.90K | -- | -- | -- |
| Cost of Revenue | 5.30K | 1.10K | -- | -- | -- |
| Gross Profit | -1.00K | 900.00 | -- | -- | -- |
| SG&A Expenses | 1.75M | 938.50K | 447.00K | 1.16M | 551.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.85M | 1.15M | 799.90K | 1.43M | 667.70K |
| Operating Income | -1.85M | -1.15M | -799.90K | -1.43M | -667.70K |
| Income Before Tax | -4.71M | -1.85M | -1.98M | -15.94M | -765.70K |
| Income Tax Expenses | -- | -- | -- | -- | 0.00 |
| Earnings from Continuing Operations | -4.71M | -1.85M | -1.98M | -15.94M | -765.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.71M | -1.85M | -1.98M | -15.94M | -765.70K |
| EBIT | -1.85M | -1.15M | -799.90K | -1.43M | -667.70K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -55.27 | -44.84 | -48.19 | -504.87 | -33.29 |
| Normalized Basic EPS | -34.54 | -28.02 | -24.59 | -35.83 | -20.81 |
| EPS Diluted | -55.27 | -44.84 | -48.19 | -504.87 | -33.29 |
| Normalized Diluted EPS | -34.54 | -28.02 | -24.59 | -35.83 | -20.81 |
| Average Basic Shares Outstanding | 85.20K | 41.30K | 41.10K | 31.60K | 23.00K |
| Average Diluted Shares Outstanding | 85.20K | 41.30K | 41.10K | 31.60K | 23.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |